Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: This study aimed to investigate [F]fluorodeoxyglucose positron emission tomography ([F]FDG PET) mapping for cerebral glucose metabolism in drug-sensitive and drug-resistant pediatric epilepsy patients.

Methods: This retrospective study enrolled 40 patients and 25 controls. Patients were categorized into drug-sensitive epilepsy (n = 22) and drug-resistant epilepsy (n = 18) according to the seizure frequency at follow-up. All patients underwent two [F]FDG PET scans separated by a minimum of one year. Absolute asymmetry index (|AI|) was calculated for assessing metabolic differences and changes in epileptic foci. Statistical Parametric Mapping (SPM) was utilized to reveal voxel-wise metabolic characteristics and alterations throughout the brain. Network analysis based on graph theory was used to investigate network-level differences between the two patient groups.

Results: The drug-sensitive group showed a lower |AI| at both baseline (P = 0.038) and follow-up (P = 0.003) PET scans than the drug-resistant group. |AI| decreased in the drug-sensitive group and increased in the drug-resistant group across scans, but these trends were not statistically significant (P = 0.240 and P = 0.450, respectively). Both groups exhibited hypometabolism at baseline. The drug-sensitive group showed less hypometabolic brain regions than the drug-resistant group. The drug-sensitive maintained stable level of hypometabolism between the two scans, whereas the drug-resistant group showed an increasing hypometabolism. Network analysis demonstrated that the drug-sensitive group had a higher global efficiency, average degree, and clustering, along with a shorter characteristic path length compared to the drug-resistant group.

Conclusions: For the first time, this study revealed in vivo cerebral glucose metabolic pattern of nonsurgical pediatric epilepsy patients treated by antiepileptic drugs. Especially, drug-resistant epilepsy patients represented significantly extensive and progressive hypometabolism with inefficient brain network connectivity compared with drug-sensitive epilepsy. [F]FDG PET imaging may be a potential visual approach for theranostics of epilepsy patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-024-06933-1DOI Listing

Publication Analysis

Top Keywords

[f]fdg pet
16
drug-sensitive group
16
drug-resistant group
16
cerebral glucose
12
drug-resistant epilepsy
12
epilepsy patients
12
drug-sensitive
9
drug-resistant
9
pet mapping
8
mapping cerebral
8

Similar Publications

PET/CT imaging of the late-gestation fetal brain in pregnant rats: A proof-of-concept study.

J Cereb Blood Flow Metab

September 2025

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Preclinical PET studies offer the opportunity to elucidate molecular mechanisms underlying early neurodevelopment with minimal invasiveness. We demonstrated the feasibility of fetal brain PET in four pregnant rats ( = 42 fetuses). [F]FDG uptake in rat fetuses was readily visualized by PET imaging.

View Article and Find Full Text PDF

Functional PET (fPET) identifies stimulation-specific changes of physiological processes, individual molecular connectivity and group-level molecular covariance. Since there is currently no consistent analysis approach available for these techniques, we present a toolbox for unified fPET assessment. The toolbox supports analysis of data obtained with a variety of radiotracers, scanners, experimental protocols, cognitive tasks and species.

View Article and Find Full Text PDF

Purpose: The liver-brain axis regulates metabolic homeostasis, with glucose metabolism playing a key role. Liver dysfunction, such as fibrosis, may impact brain metabolism and consequently, brain function. Positron emission tomography (PET) imaging provides a non-invasive approach to study glucose metabolism in both organs.

View Article and Find Full Text PDF

Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).

View Article and Find Full Text PDF